Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

Emilio Bajetta, Maria Di Bartolomeo, Roberto Buzzoni, Erminia Ferrario, Katia F. Dotti, Luigi Mariani, Roberto Bajetta, Arpine Gevorgyan, Paola Venturino, Margherita Galassi

Research output: Contribution to journalArticle

Abstract

Purpose: This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. Methods: Five dose level combinations with irinotecan (from 180 to 240 mg/m2, day 1, q21), capecitabine (1,500-2,000 mg/m2 per day, days 2-15, q21) and erlotinib (50-150 mg per day, continuously) were planned. Patients were enrolled in cohorts of three, and evaluated for first cycle acute toxicity. Results: Twenty-one patients were treated. In the first cohort, no DLT was reported, in the second: one DLT (G4 neutropenic fever associated with G3 cutaneous rash and mucositis); in the third dose level: two DLT (G3 diarrhea and G4 neutropenic fever). To confirm these results, other six patients were additionally included and no DLT was observed. Conclusions: The results documented that erlotinib at the dose of 100 mg per day, irinotecan 180 mg/m2 and capecitabine 1,500 mg/m2 per day for 14 days has an acceptable safety profile and appears suitable for further phase II studies.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number1
DOIs
Publication statusPublished - Jun 2009

Keywords

  • Capecitabine
  • Colorectal cancer
  • Erlotinib
  • Irinotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this